Group 1 - The core viewpoint of the articles emphasizes that 2025 was a year of rational value and long-termism for the biopharmaceutical industry, rather than a winter or bubble phase [1] - The company achieved significant milestones, including the successful listing on the Hong Kong Stock Exchange on December 30, 2025, becoming the largest biotech company by financing scale in the Hong Kong market that year [1] - The company established collaborations with major pharmaceutical firms such as Eli Lilly, Sihuan Pharmaceutical, and Fosun Pharma, and made progress in clinical and preclinical projects [1] Group 2 - In the AI pharmaceutical sector, AI has transitioned from being viewed as a "black box" to a foundational element, with more pharmaceutical companies adopting and deploying AI technologies [2] - The company has gained trust from the industry and partners through its benchmark capabilities in AI drug development and continuous output of preclinical candidates [2] - Looking ahead to 2026, the company aims to expand into broader life sciences areas and explore new molecular entities, including the establishment of an AI-driven automated peptide screening platform [2]
英矽智能联合首席执行官任峰：持续拓展更广阔的边界